vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and ASCENT INDUSTRIES CO. (ACNT). Click either name above to swap in a different company.
ASCENT INDUSTRIES CO. is the larger business by last-quarter revenue ($11.9M vs $10.7M, roughly 1.1× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -8.8%, a 32.3% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 13.3%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -34.9%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
ASCENT INDUSTRIES CO.ACNTEarnings & Financial Report
Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.
ABUS vs ACNT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $11.9M |
| Net Profit | $2.5M | $-1.0M |
| Gross Margin | — | 14.6% |
| Operating Margin | 13.9% | -21.0% |
| Net Margin | 23.5% | -8.8% |
| Revenue YoY | 522.2% | 13.3% |
| Net Profit YoY | 112.7% | -1.2% |
| EPS (diluted) | $0.01 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.9M | ||
| Q3 25 | — | $19.7M | ||
| Q2 25 | $10.7M | $18.7M | ||
| Q1 25 | — | $24.7M | ||
| Q4 24 | — | $10.5M | ||
| Q3 24 | — | $20.9M | ||
| Q2 24 | — | $21.5M | ||
| Q1 24 | — | $28.0M |
| Q4 25 | — | $-1.0M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $2.5M | $6.3M | ||
| Q1 25 | — | $-2.3M | ||
| Q4 24 | — | $-1.0M | ||
| Q3 24 | — | $-6.2M | ||
| Q2 24 | — | $-926.0K | ||
| Q1 24 | — | $-5.5M |
| Q4 25 | — | 14.6% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | — | 26.1% | ||
| Q1 25 | — | 19.3% | ||
| Q4 24 | — | 24.3% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 13.1% | ||
| Q1 24 | — | 8.3% |
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -4.1% | ||
| Q2 25 | 13.9% | -14.4% | ||
| Q1 25 | — | -4.2% | ||
| Q4 24 | — | -25.4% | ||
| Q3 24 | — | -9.4% | ||
| Q2 24 | — | -8.6% | ||
| Q1 24 | — | -15.5% |
| Q4 25 | — | -8.8% | ||
| Q3 25 | — | -10.6% | ||
| Q2 25 | 23.5% | 33.7% | ||
| Q1 25 | — | -9.3% | ||
| Q4 24 | — | -9.8% | ||
| Q3 24 | — | -29.5% | ||
| Q2 24 | — | -4.3% | ||
| Q1 24 | — | -19.7% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $-0.22 | ||
| Q2 25 | $0.01 | $0.65 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.61 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $57.6M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $87.0M |
| Total Assets | $103.3M | $111.9M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $57.6M | ||
| Q3 25 | — | $58.0M | ||
| Q2 25 | $37.4M | $60.5M | ||
| Q1 25 | — | $14.3M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | — | $8.5M | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $1.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $87.0M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | $83.0M | $89.7M | ||
| Q1 25 | — | $91.2M | ||
| Q4 24 | — | $93.5M | ||
| Q3 24 | — | $94.7M | ||
| Q2 24 | — | $101.0M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | — | $111.9M | ||
| Q3 25 | — | $119.9M | ||
| Q2 25 | $103.3M | $122.6M | ||
| Q1 25 | — | $152.5M | ||
| Q4 24 | — | $147.3M | ||
| Q3 24 | — | $148.6M | ||
| Q2 24 | — | $158.2M | ||
| Q1 24 | — | $161.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $266.0K |
| Free Cash FlowOCF − Capex | — | $-196.0K |
| FCF MarginFCF / Revenue | — | -1.7% |
| Capex IntensityCapex / Revenue | 0.0% | 3.9% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $266.0K | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | $-15.7M | $-1.4M | ||
| Q1 25 | — | $-700.0K | ||
| Q4 24 | — | $8.8M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $2.2M | ||
| Q1 24 | — | $263.0K |
| Q4 25 | — | $-196.0K | ||
| Q3 25 | — | $695.0K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.0M | ||
| Q4 24 | — | $8.4M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $25.0K |
| Q4 25 | — | -1.7% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | -8.3% | ||
| Q1 25 | — | -4.1% | ||
| Q4 24 | — | 80.6% | ||
| Q3 24 | — | 15.1% | ||
| Q2 24 | — | 9.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | 3.9% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | -0.22× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
